Glenmark Launches FabiFlu (favipiravir) as the First Oral Medication to Treat Mild to Moderate COVID-19 in India
Shots:
- Glenmark has received manufacturing and marketing approval for its antiviral drug FabiFlu (favipiravir) to treat COVID-19 in India. The drug will be available as a prescribed therapy for INR 103/tablet with recommended dose being 1800mg (bid) on day 1- followed by 800mg (bid) up to day 14
- Favipiravir demonstrated clinical improvements of up to 88% in SARS-CoV-2 virus infection- with rapid reduction in viral load by 4 days across the age groups 20 to >90yrs.- including in patients with co-morbid conditions like diabetes and heart disease suffering from mild to moderate COVID-19
- The drug receives MHLW’s approval in 2014 to treat novel or re-emerging influenza virus infections. Additionally- the company has initiated clinical trial to evaluate the efficacy of two antivirals Favipiravir and Umifenovir as a combination therapy in moderate hospitalized adult COVID-19 patients in India
Click here to read full press release/ article | Ref: Businesswire | Image: Bloomlive
Related News: Glenmark to Initiate P-III Clinical Study Evaluating the Combination Therapy for Hospitalized Patients with COVID-19 in India
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com
